^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gefitinib

    i
    Company:
    Generic mfg.
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03122717)
    Phase 1/2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    09/26/2024
    Initiation :
    05/09/2017
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • gefitinib
    Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU) (NCT04322890)
    Phase 2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2020
    Primary completion :
    12/24/2026
    Completion :
    12/24/2027
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
    |
    cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)
    A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (NCT02411448)
    Phase 3
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    03/18/2024
    Initiation :
    05/06/2015
    Primary completion :
    01/23/2019
    Completion :
    12/16/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib • Cyramza (ramucirumab)
    Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer (NCT03647592)
    Phase N/A
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    06/01/2018
    Primary completion :
    08/31/2024
    Completion :
    12/01/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Avastin (bevacizumab) • erlotinib • gefitinib
    Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2) (NCT04401059)
    Phase 4
    Tian Xie
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    11/09/2020
    Primary completion :
    09/30/2025
    Completion :
    03/30/2026
    EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1
    |
    EGFR mutation • EGFR L858R • EGFR positive
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)
    Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy (SIIS) (NCT01485809)
    Phase 2
    Seoul Veterans Hospital
    Completed
    Last update posted :
    11/24/2023
    Initiation :
    10/01/2011
    Primary completion :
    10/01/2011
    Completion :
    11/01/2016
    EGFR
    |
    EGFR mutation
    |
    gefitinib
    ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. (ARCHER 1050) (NCT01774721)
    Phase 3
    Pfizer
    Completed
    Last update posted :
    11/14/2023
    Initiation :
    05/09/2013
    Primary completion :
    07/29/2016
    Completion :
    01/27/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    gefitinib • Vizimpro (dacomitinib)
    Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients (NCT06071013)
    Phase 2
    China Medical University Hospital
    Not yet recruiting
    Last update posted :
    10/06/2023
    Initiation :
    09/28/2023
    Primary completion :
    08/27/2026
    Completion :
    08/27/2026
    EGFR
    |
    EGFR mutation • EGFR positive
    |
    erlotinib • Gilotrif (afatinib) • gefitinib • nintedanib
    Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) (NCT01833572)
    Phase 2
    Fudan University
    Completed
    Last update posted :
    07/12/2023
    Initiation :
    05/01/2013
    Primary completion :
    10/01/2015
    Completion :
    10/01/2015
    EGFR
    |
    EGFR mutation • EGFR exon 19 deletion
    |
    gefitinib
    The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG) (NCT04179890)
    Phase N/A
    Boehringer Ingelheim
    Completed
    Last update posted :
    05/25/2023
    Initiation :
    12/17/2019
    Primary completion :
    07/22/2021
    Completion :
    07/22/2021
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR T790M
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib
    Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) (NCT01982955)
    Phase 1/2
    Merck KGaA, Darmstadt, Germany
    Completed
    Last update posted :
    11/08/2022
    Initiation :
    12/23/2013
    Primary completion :
    12/12/2017
    Completion :
    10/14/2021
    MET
    |
    EGFR mutation • MET amplification • MET overexpression
    |
    cisplatin • carboplatin • gefitinib • pemetrexed • Tepmetko (tepotinib)
    Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative (NCT03758287)
    Phase 1/2
    Sunshine Lake Pharma Co., Ltd.
    Active, not recruiting
    Last update posted :
    06/22/2022
    Initiation :
    11/01/2016
    Primary completion :
    07/17/2023
    Completion :
    07/17/2023
    MET
    |
    EGFR mutation • EGFR T790M negative
    |
    gefitinib • ningetinib (CT053PTSA)
    Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors (NCT02447419)
    Phase 2
    Samsung Medical Center
    Completed
    Last update posted :
    06/15/2022
    Initiation :
    12/03/2014
    Primary completion :
    06/01/2020
    Completion :
    12/01/2020
    EGFR
    |
    EGFR amplification • EGFR overexpression
    |
    gefitinib
    Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib (NCT00522145)
    Phase 2
    Kadmon Corporation, LLC
    Completed
    Last update posted :
    05/13/2022
    Initiation :
    05/01/2007
    Primary completion :
    10/01/2009
    Completion :
    02/01/2010
    EGFR
    |
    EGFR mutation • EGFR T790M
    |
    erlotinib • gefitinib • tesevatinib (KD019)
    PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery (NCT02804776)
    Phase 2
    National Cancer Centre, Singapore
    Completed
    Last update posted :
    06/02/2021
    Initiation :
    01/27/2015
    Primary completion :
    02/21/2018
    Completion :
    02/21/2018
    EGFR • KRAS • ALK
    |
    EGFR mutation
    |
    gefitinib
    JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety (NCT04874844)
    Phase 2/3
    Beijing Dongfang Biotech Co., Ltd.
    Not yet recruiting
    Last update posted :
    05/10/2021
    Initiation :
    07/30/2021
    Primary completion :
    03/30/2022
    Completion :
    06/30/2023
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    erlotinib • gefitinib • JY025
    A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment (CINC280X2202) (NCT01610336)
    Phase 2
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    04/08/2021
    Initiation :
    04/05/2012
    Primary completion :
    06/10/2016
    Completion :
    05/27/2020
    MET
    |
    EGFR mutation
    |
    gefitinib • Tabrecta (capmatinib)
    Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib (NCT02747953)
    Phase 2
    Samsung Medical Center
    Completed
    Last update posted :
    03/19/2021
    Initiation :
    07/01/2011
    Primary completion :
    12/01/2014
    Completion :
    11/01/2016
    EGF
    |
    erlotinib • Gilotrif (afatinib) • gefitinib
    Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR (LADIE) (NCT01556191)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Completed
    Last update posted :
    01/08/2021
    Initiation :
    05/15/2012
    Primary completion :
    05/15/2018
    Completion :
    06/17/2020
    EGFR
    |
    EGFR mutation • EGFR wild-type
    |
    erlotinib • gefitinib • fulvestrant
    Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme (NCT00052208)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/30/2020
    Initiation :
    03/01/2002
    Primary completion :
    06/01/2005
    EGFR
    |
    gefitinib
    Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer (NCT00553254)
    Phase 2
    Pfizer
    Completed
    Last update posted :
    10/19/2020
    Initiation :
    02/05/2008
    Primary completion :
    08/03/2010
    Completion :
    07/17/2014
    HER-2 • KRAS
    |
    EGFR mutation • HER-2 mutation • KRAS wild-type
    |
    erlotinib • gefitinib • Vizimpro (dacomitinib)
    A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (NCT01544179)
    Phase 3
    AstraZeneca
    Completed
    Last update posted :
    09/25/2020
    Initiation :
    03/15/2012
    Primary completion :
    05/05/2014
    Completion :
    11/20/2019
    EGFR
    |
    EGFR mutation
    |
    cisplatin • gefitinib • pemetrexed
    Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance (NCT03267654)
    Phase 2
    Qilu Pharmaceutical Co., Ltd.
    Unknown status
    Last update posted :
    08/03/2020
    Initiation :
    10/12/2017
    Primary completion :
    10/20/2020
    Completion :
    12/30/2021
    EGFR • BCL2
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • BCL2L11 deletion
    |
    carboplatin • gefitinib • AiTan (rivoceranib)
    S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC (NCT03457337)
    Phase 2
    Henan Cancer Hospital
    Unknown status
    Last update posted :
    07/10/2020
    Initiation :
    03/28/2018
    Primary completion :
    10/31/2020
    Completion :
    10/31/2021
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    gefitinib • Teysuno (gimeracil/oteracil/tegafur)
    Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC (NCT04425187)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    06/12/2020
    Initiation :
    06/08/2020
    Primary completion :
    12/31/2021
    Completion :
    12/31/2022
    EGFR
    |
    EGFR mutation • EGFR L858R
    |
    Avastin (bevacizumab) • gefitinib
    Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib (NCT04358562)
    Phase 2
    Second Affiliated Hospital of Nanchang University
    Not yet recruiting
    Last update posted :
    04/24/2020
    Initiation :
    05/01/2020
    Primary completion :
    05/01/2022
    Completion :
    11/01/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    gefitinib • Focus V (anlotinib)
    LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung (NCT01466660)
    Phase 2b
    Boehringer Ingelheim
    Completed
    Last update posted :
    04/07/2020
    Initiation :
    12/13/2011
    Primary completion :
    04/08/2016
    Completion :
    04/12/2019
    EGFR
    |
    EGFR mutation • EGFR L858R
    |
    Gilotrif (afatinib) • gefitinib
    Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation (ADJUVANT) (NCT01405079)
    Phase 3
    Guangdong Association of Clinical Trials
    Unknown status
    Last update posted :
    02/18/2020
    Initiation :
    09/19/2011
    Primary completion :
    03/01/2017
    Completion :
    12/01/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • gefitinib • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    Third-line Treatment of Gefitinib in NSCLC Patients (NCT01933347)
    Phase 2
    Guangdong Association of Clinical Trials
    Completed
    Last update posted :
    02/06/2020
    Initiation :
    04/07/2014
    Primary completion :
    04/10/2017
    Completion :
    04/10/2018
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    gefitinib
    Anticancer Activity of Nicotinamide on Lung Cancer (NCT02416739)
    Phase 2/3
    Il Yeong Park, Ph.D.
    Unknown status
    Last update posted :
    01/27/2020
    Initiation :
    03/01/2015
    Primary completion :
    03/01/2020
    Completion :
    06/01/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    erlotinib • gefitinib
    Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations (NCT03529084)
    Phase 3
    Novartis Pharmaceuticals
    Withdrawn
    Last update posted :
    11/22/2019
    Initiation :
    07/24/2018
    Primary completion :
    08/13/2020
    Completion :
    06/03/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    erlotinib • gefitinib • nazartinib (EGF816)
    Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (FL-ALTER) (NCT04028778)
    Phase 3
    Sun Yat-sen University
    Recruiting
    Last update posted :
    11/08/2019
    Initiation :
    04/10/2019
    Primary completion :
    12/01/2020
    Completion :
    12/01/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    gefitinib • Focus V (anlotinib)
    A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) (NCT01469000)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    09/10/2019
    Initiation :
    02/01/2012
    Primary completion :
    04/01/2015
    Completion :
    11/01/2017
    EGFR
    |
    EGFR mutation • EGFR expression
    |
    gefitinib • pemetrexed
    Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer (NCT00027690)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/23/2019
    Initiation :
    06/01/2002
    Primary completion :
    09/01/2004
    Completion :
    07/01/2013
    EGFR
    |
    gefitinib
    Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI (NCT04007835)
    Phase N/A
    Guangdong Association of Clinical Trials
    Unknown status
    Last update posted :
    07/05/2019
    Initiation :
    07/01/2019
    Primary completion :
    07/01/2021
    Completion :
    12/01/2021
    EGFR
    |
    EGFR mutation • EGFR exon 19 deletion
    |
    erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)
    Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma (NCT00282100)
    Phase 2
    Tan Tock Seng Hospital
    Unknown status
    Last update posted :
    04/16/2019
    Initiation :
    12/01/2005
    Primary completion :
    09/01/2019
    Completion :
    09/01/2019
    AFP
    |
    gefitinib
    Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma (NCT02929693)
    Phase 3
    Shanghai University of Traditional Chinese Medi...
    Unknown status
    Last update posted :
    04/11/2019
    Initiation :
    10/01/2016
    Primary completion :
    06/01/2019
    Completion :
    06/01/2019
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    gefitinib
    Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation (NCT03856697)
    Phase 3
    Hangzhou ACEA Pharmaceutical Research Co., Ltd.
    Not yet recruiting
    Last update posted :
    02/27/2019
    Initiation :
    03/01/2019
    Primary completion :
    03/01/2022
    Completion :
    03/01/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    gefitinib • Fujovee (abivertinib)
    Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer (NCT03766490)
    Phase N/A
    The First Affiliated Hospital of Soochow Univer...
    Unknown status
    Last update posted :
    01/30/2019
    Initiation :
    03/30/2019
    Primary completion :
    12/20/2019
    Completion :
    12/20/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    gefitinib • Focus V (anlotinib) • Conmana (icotinib)
    A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. (NCT03381066)
    Phase 3
    Yonsei University
    Recruiting
    Last update posted :
    01/11/2019
    Initiation :
    04/10/2018
    Primary completion :
    12/01/2022
    Completion :
    12/01/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • gefitinib • pemetrexed • vinorelbine tartrate